Developer docs
API playgroundTry for free, no card

Search company profiles

Nanite

Full company profile

uuid0000xqo

Namestring
Nanite
Legal namestring
Nanite Inc.
Websiteurl
nanitebio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nanite is a Boston-based, privately held biotechnology company founded in 2021 that develops AI-designed polymer nanoparticles (PNPs) for non-viral gene delivery. The company's core technology is the SAYER™ platform, a high-throughput closed-loop system that integrates computational design, rapid polymer synthesis, and first-principles characterization with machine learning to rationally engineer delivery vehicles with tissue-specific targeting. Nanite's PNPs are positioned as a third alternative to viral vectors and lipid nanoparticles, offering resorbable, modular, thermally stable, and re-doseable carriers for DNA, mRNA, and DNA-encoded biologics. In 2025 the company introduced ChainSpace™, a sequence-first polymer design framework, and demonstrated 56-day durability of DNA-encoded antibody expression in vivo, alongside 85% transfection efficiency in optimized polymer designs.

Nanite operates a B2B go-to-market model centered on strategic research collaborations with pharmaceutical and biotech companies (notably SalioGen Therapeutics for cystic fibrosis co-development) and grant-funded programs with disease-focused foundations including the Bill & Melinda Gates Foundation ($1.8M for HIV) and the Cystic Fibrosis Foundation (up to $2M for lung delivery). Customer segments include genetic therapy developers focused on lung indications, global health therapeutics organizations, and cell and gene therapy companies pursuing CAR-T and in vivo gene editing applications. The company is pre-commercial, with 11-50 employees, and has raised approximately $9.8 million across a $6M seed round led by Zetta Venture Partners and foundation grants.

The company is led by co-founders Sean Kevlahan (CEO, PhD in Chemical Engineering, former Bio-Techne cell and gene therapy division head and Quad Technologies founder acquired by Bio-Techne) and Thomas Neenan (CBO, PhD in materials chemistry, co-founder of Panbela Therapeutics and AbFero Pharmaceuticals). Its technology has been validated through peer-reviewed publication including a Journal of Polymer Chemistry cover feature, and Nanite maintains an active scientific publishing and conference presence as a top-of-funnel channel.

Short descriptiontext

Nanite is a Boston-based biotech developing AI-designed polymer nanoparticles for non-viral gene delivery, serving pharmaceutical partners and research foundations across cystic fibrosis, HIV, and cell therapy applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-viral gene delivery, polymer nanoparticles, AI drug design, gene therapy platform, DNA-encoded biologics
Industry2 codes
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Nanotechnology541713
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Non-Viral Gene Delivery Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Grants
TypeManaged Services
Description

Grant funding from foundations (Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation) for specific therapeutic development programs

biospace.com
2Strategic Research Collaborations
TypeProfessional Services
Description

B2B partnerships with pharmaceutical and biotech companies for development of targeted nanoparticle delivery systems

vcnewsdaily.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nanite designs and develops polymer nanoparticles (PNPs) for non-viral gene delivery through its SAYER™ platform, which combines AI, high-throughput synthesis, and first-principles characterization to engineer tissue-specific delivery vehicles for DNA, mRNA, and DNA-encoded biologics. The company monetizes via B2B research collaborations with pharmaceutical/biotech firms and grant-funded development with research foundations, rather than selling finished therapeutic products. Its deliverables include AI-designed PNP candidates, the ChainSpace™ polymer design framework, and co-developed therapeutic delivery programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85% transfection efficiency achieved with optimized polymer design
+4 more records
Product overview1 text field

Nanite offers a unified platform architecture centered on its SAYER™ AI-driven system for designing polymer nanoparticles (PNPs) for non-viral gene delivery. The core product is the SAYER platform, which combines high-throughput synthesis, computational design, and machine learning to create precision delivery vehicles. Supporting capabilities include the ChainSpace™ framework for polymer sequence design and DNA-encoded biologics delivery applications. Together, these products enable programmable, targeted, and safe delivery of genetic cargoes for a broad range of therapeutic modalities including antibodies, enzymes, and peptides.

Product and service4 records
1SAYER™ Platform
CategoryCore Platform / Software
2Polymer Nanoparticles (PNPs)
CategoryCore Product / Delivery Vehicle
3ChainSpace™
CategoryPlatform Feature / Software Framework
4DNA-Encoded Biologics Delivery
CategoryTherapeutic Application / Delivery Service
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-29
Description

Strategic research collaboration to develop a lung-targeting polymer nanoparticle for cystic fibrosis. Nanite's SAYER platform will be used to create a PNP designed to integrate the CFTR gene directly into lung cells using SalioGen's novel Gene Coding technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Beam is a clinical-stage base-editing company with active programs in non-viral delivery for in vivo gene editing. It shares Nanite's interest in tissue-specific, re-doseable delivery vehicles and competes for the same pharma partnership capital.

TypeEmerging player
Description

Verve develops in vivo gene editing therapies for cardiovascular disease, requiring efficient non-viral delivery to the liver and other tissues. It is a comparable emerging player whose delivery needs overlap with Nanite's tissue-targeting value proposition.

TypeDirect peer
Description

Genevant licenses LNP and other lipid-based delivery technology for RNA therapeutics. It competes head-to-head with Nanite in the non-viral delivery space and serves a similar pharma/biotech partner base.

TypeEmerging player
Description

SalioGen is Nanite's named co-development partner for a lung-targeting PNP leveraging SalioGen's Gene Coding™ technology for CF. It is a peer on the non-viral gene integration frontier even as it acts as a customer in the CF program.

TypeBroad incumbent
Description

Intellia is a clinical-stage in vivo CRISPR/Cas9 gene editing company actively investing in next-generation delivery — including non-LNP and polymer-based approaches — to expand beyond LNP's tissue reach, making it a meaningful comparable in non-viral delivery strategy.

TypeEmerging player
Description

Strand is a programmable mRNA therapeutics company developing self-replicating and tunable expression systems, often paired with novel delivery approaches. It is an emerging peer in the engineered-nucleic-acid-delivery category where Nanite also competes.

TypeBroad incumbent
Description

BioNTech commercialized LNP-delivered mRNA vaccines at scale and continues to invest in next-generation delivery. It represents a broad incumbent that any polymer-based delivery competitor must displace or partner around.

TypeDirect peer
Description

Arcturus develops lipid-mediated delivery systems for mRNA and self-amplifying RNA therapeutics. It overlaps with Nanite on the non-viral delivery axis and on partnering economics with larger pharma for nucleic-acid-based drugs.

TypeDirect peer
Description

Acuitas develops lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics and is the LNP provider behind Pfizer/BioNTech's COVID-19 vaccine. It is the most direct non-viral delivery comparator to Nanite's PNP platform, addressing the same customers and therapeutic cargoes.

TypeBroad incumbent
Description

Moderna is the dominant LNP-mRNA platform company with massive capital, manufacturing, and clinical experience. It defines the incumbent competitive context against which any non-viral delivery startup — including Nanite — must justify a differentiated approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanite

Non-Viral Gene Delivery Technologynanitebio.com

Nanite is a Boston-based biotech developing AI-designed polymer nanoparticles for non-viral gene delivery, serving pharmaceutical partners and research foundations across cystic fibrosis, HIV, and cell therapy applications.

What Nanite does

Nanite is a Boston-based, privately held biotechnology company founded in 2021 that develops AI-designed polymer nanoparticles (PNPs) for non-viral gene delivery. The company's core technology is the SAYER™ platform, a high-throughput closed-loop system that integrates computational design, rapid polymer synthesis, and first-principles characterization with machine learning to rationally engineer delivery vehicles with tissue-specific targeting. Nanite's PNPs are positioned as a third alternative to viral vectors and lipid nanoparticles, offering resorbable, modular, thermally stable, and re-doseable carriers for DNA, mRNA, and DNA-encoded biologics. In 2025 the company introduced ChainSpace™, a sequence-first polymer design framework, and demonstrated 56-day durability of DNA-encoded antibody expression in vivo, alongside 85% transfection efficiency in optimized polymer designs.

Nanite operates a B2B go-to-market model centered on strategic research collaborations with pharmaceutical and biotech companies (notably SalioGen Therapeutics for cystic fibrosis co-development) and grant-funded programs with disease-focused foundations including the Bill & Melinda Gates Foundation ($1.8M for HIV) and the Cystic Fibrosis Foundation (up to $2M for lung delivery). Customer segments include genetic therapy developers focused on lung indications, global health therapeutics organizations, and cell and gene therapy companies pursuing CAR-T and in vivo gene editing applications. The company is pre-commercial, with 11-50 employees, and has raised approximately $9.8 million across a $6M seed round led by Zetta Venture Partners and foundation grants.

The company is led by co-founders Sean Kevlahan (CEO, PhD in Chemical Engineering, former Bio-Techne cell and gene therapy division head and Quad Technologies founder acquired by Bio-Techne) and Thomas Neenan (CBO, PhD in materials chemistry, co-founder of Panbela Therapeutics and AbFero Pharmaceuticals). Its technology has been validated through peer-reviewed publication including a Journal of Polymer Chemistry cover feature, and Nanite maintains an active scientific publishing and conference presence as a top-of-funnel channel.

Nanite firmographics

Firmographics
Name
Nanite
Legal name
Nanite Inc.
Website
https://nanitebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Nanite is a Boston-based biotech developing AI-designed polymer nanoparticles for non-viral gene delivery, serving pharmaceutical partners and research foundations across cystic fibrosis, HIV, and cell therapy applications.
Ownership category
akta.pro rank

Nanite industry classification

Industry
Product category
Non-Viral Gene Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Non-viral gene delivery
  • Polymer nanoparticles
  • AI drug design
  • Gene therapy platform
  • DNA-encoded biologics

Where Nanite is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nanite business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research Grants: Grant funding from foundations (Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation) for specific therapeutic development programs
  2. Strategic Research Collaborations: B2B partnerships with pharmaceutical and biotech companies for development of targeted nanoparticle delivery systems

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Nanite product offering

Product offering

Core offering

Nanite designs and develops polymer nanoparticles (PNPs) for non-viral gene delivery through its SAYER™ platform, which combines AI, high-throughput synthesis, and first-principles characterization to engineer tissue-specific delivery vehicles for DNA, mRNA, and DNA-encoded biologics. The company monetizes via B2B research collaborations with pharmaceutical/biotech firms and grant-funded development with research foundations, rather than selling finished therapeutic products. Its deliverables include AI-designed PNP candidates, the ChainSpace™ polymer design framework, and co-developed therapeutic delivery programs.

Product overview

Nanite offers a unified platform architecture centered on its SAYER™ AI-driven system for designing polymer nanoparticles (PNPs) for non-viral gene delivery. The core product is the SAYER platform, which combines high-throughput synthesis, computational design, and machine learning to create precision delivery vehicles. Supporting capabilities include the ChainSpace™ framework for polymer sequence design and DNA-encoded biologics delivery applications. Together, these products enable programmable, targeted, and safe delivery of genetic cargoes for a broad range of therapeutic modalities including antibodies, enzymes, and peptides.

Differentiator

Problem solved

Functional benefit

Products and services

  • SAYER™ Platform
  • Polymer Nanoparticles (PNPs)
  • ChainSpace™
  • DNA-Encoded Biologics Delivery

Quantifiable outcome

  • 85% transfection efficiency achieved with optimized polymer design
  • +4 more outcomes

Companies that use Nanite

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Nanite technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Nanite partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SalioGen TherapeuticscoreStrategic or Co-development Partner · 29 May 2024Strategic research collaboration to develop a lung-targeting polymer nanoparticle for cystic fibrosis. Nanite's SAYER platform will be used to create a PNP designed to integrate the CFTR gene directly into lung cells using SalioGen's novel Gene Coding technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Nanite competitors and assessment

Company assessment

Broad incumbents

  • Beam Therapeutics: Beam is a clinical-stage base-editing company with active programs in non-viral delivery for in vivo gene editing. It shares Nanite's interest in tissue-specific, re-doseable delivery vehicles and competes for the same pharma partnership capital.
  • Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR/Cas9 gene editing company actively investing in next-generation delivery — including non-LNP and polymer-based approaches — to expand beyond LNP's tissue reach, making it a meaningful comparable in non-viral delivery strategy.
  • BioNTech: BioNTech commercialized LNP-delivered mRNA vaccines at scale and continues to invest in next-generation delivery. It represents a broad incumbent that any polymer-based delivery competitor must displace or partner around.
  • Moderna: Moderna is the dominant LNP-mRNA platform company with massive capital, manufacturing, and clinical experience. It defines the incumbent competitive context against which any non-viral delivery startup — including Nanite — must justify a differentiated approach.

Emerging players

  • Verve Therapeutics: Verve develops in vivo gene editing therapies for cardiovascular disease, requiring efficient non-viral delivery to the liver and other tissues. It is a comparable emerging player whose delivery needs overlap with Nanite's tissue-targeting value proposition.
  • SalioGen Therapeutics: SalioGen is Nanite's named co-development partner for a lung-targeting PNP leveraging SalioGen's Gene Coding™ technology for CF. It is a peer on the non-viral gene integration frontier even as it acts as a customer in the CF program.
  • Strand Therapeutics: Strand is a programmable mRNA therapeutics company developing self-replicating and tunable expression systems, often paired with novel delivery approaches. It is an emerging peer in the engineered-nucleic-acid-delivery category where Nanite also competes.

Direct peers

  • Genevant Sciences: Genevant licenses LNP and other lipid-based delivery technology for RNA therapeutics. It competes head-to-head with Nanite in the non-viral delivery space and serves a similar pharma/biotech partner base.
  • Arcturus Therapeutics: Arcturus develops lipid-mediated delivery systems for mRNA and self-amplifying RNA therapeutics. It overlaps with Nanite on the non-viral delivery axis and on partnering economics with larger pharma for nucleic-acid-based drugs.
  • Acuitas Therapeutics: Acuitas develops lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics and is the LNP provider behind Pfizer/BioNTech's COVID-19 vaccine. It is the most direct non-viral delivery comparator to Nanite's PNP platform, addressing the same customers and therapeutic cargoes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Nanite social profiles

Digital presence

Nanite financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanite leadership team

Management profile

Number of profiles

Profiles8 records

Nanite funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanite M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanite

What does Nanite do?

Nanite designs and develops polymer nanoparticles (PNPs) for non-viral gene delivery through its SAYER™ platform, which combines AI, high-throughput synthesis, and first-principles characterization to engineer tissue-specific delivery vehicles for DNA, mRNA, and DNA-encoded biologics. The company monetizes via B2B research collaborations with pharmaceutical/biotech firms and grant-funded development with research foundations, rather than selling finished therapeutic products. Its deliverables include AI-designed PNP candidates, the ChainSpace™ polymer design framework, and co-developed therapeutic delivery programs.

Is Nanite a public or private company?

Nanite is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanite founded?

Nanite was founded in 2021. It employs 11 to 50 people.

Where is Nanite based?

Nanite is headquartered in Boston, United States, in the North America region.

How does Nanite make money?

Two revenue lines are on record. Research Grants are the primary driver. The others are strategic Research Collaborations.

Who are Nanite's main competitors?

Broad incumbents on record are Beam Therapeutics, Intellia Therapeutics, BioNTech and Moderna. Emerging players are Verve Therapeutics, SalioGen Therapeutics and Strand Therapeutics. Direct peers are Genevant Sciences, Arcturus Therapeutics and Acuitas Therapeutics.

Does Nanite have an API?

No public API is recorded for Nanite.

What industry is Nanite in?

Nanite's product category is Non-Viral Gene Delivery Technology. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNanite Announces Strategic Collaboration with SalioGen Therapeutics to Develop Non-Viral, Lung-Targeting Nanoparticle for Cystic Fibrosis Genetic MedicineNanite, Inc. and SalioGen Therapeutics announced a research collaboration to develop a non-viral, lung-targeting polymer nanoparticle for cystic fibrosis genetic medicine, combining Nanite's SAYER™ delivery platform with SalioGen's Gene Coding™ technology. In vitro experiments have already demonstrated successful integration of the full-length CFTR gene into human lung cells, with the companies aiming to create what they describe as the first permanent therapy for people with cystic fibrosis regardless of mutation type. The collaboration positions both companies to potentially overcome limitations of existing viral vectors and lipid nanoparticles in gene therapy delivery.MoomooNANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIVNanite, Inc. has been awarded a $1.8 million grant from the Bill & Melinda Gates Foundation to develop AI-driven gene therapy aimed at HIV treatment. This funding will support the design of polymeric delivery vehicles utilizing Nanite's SAYERTM platform, potentially leading to improved therapeutic outcomes, especially for underserved populations. If successful, this research could represent a significant advance in HIV management and accessibility to gene therapies.BioSpaceNanite Awarded $1.8M to Develop AI-driven Gene Therapy for HIVNanite, Inc. has been awarded a $1.8 million grant from the Bill & Melinda Gates Foundation to develop AI-driven polymeric delivery vehicles for HIV gene therapy. The project utilizes Nanite's proprietary SAYER platform to create non-viral nanoparticles capable of expressing neutralizing antibodies in vivo. Success in this research could provide a transformative treatment for HIV, particularly improving accessibility for underserved populations.PR NewswireNANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIVNanite, Inc. has received a $1.8 million grant from the Bill & Melinda Gates Foundation to develop AI-driven polymeric delivery vehicles for HIV gene therapy. The company will utilize its proprietary SAYER platform to create non-viral nanoparticles capable of expressing neutralizing antibodies in vivo. This initiative aims to provide accessible genetic medicine solutions for underserved populations.VC News DailyNanite Receives Up to $2M InvestmentNanite Inc. announced an investment of up to $2 million from the Cystic Fibrosis Foundation to develop gene delivery technologies for lung treatments. This funding builds upon a previously announced $6 million seed financing round completed by the Boston-based company.BioSpaceNanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the LungNanite Inc. has secured up to $2 million in funding from the Cystic Fibrosis Foundation to develop polymer nanoparticle technologies for delivering genetic therapies to lungs affected by cystic fibrosis. This investment builds upon a previously announced $6 million seed round and aims to leverage Nanite's AI-driven SAYER platform to create stable, non-viral delivery vehicles. The company intends to initially target lung tissue before potentially expanding to other organs impacted by the disease.FinSMEsNanite Receives Up To $2M Investment from Cystic Fibrosis FoundationNanite, a Boston-based non-viral gene delivery company, secured up to $2 million in funding led by the Cystic Fibrosis Foundation. The company intends to use these funds to develop polymer nanoparticles capable of delivering mRNA therapies specifically to lungs affected by cystic fibrosis. This investment follows a recently announced $6 million seed financing round.VC News DailyNanite Announces $6M Seed Investment RoundNanite Inc. announced the closing of a $6 million seed investment round led by Zetta Venture Partners with participation from Arkitekt Ventures. The funding is intended to advance Nanite's AI-driven polymer design platform focused on next-generation, non-viral gene delivery.PharmiWeb.comNanite Debuts AI-Driven Polymer Design Platform for Gene DeliveryNanite Inc. announced the closing of a $6 million seed investment round led by Zetta Venture Partners to advance its AI-driven polymer design platform for gene delivery. The company's proprietary SAYER™ platform utilizes machine learning and automated synthesis to design programmable polymer nanoparticles, aiming to overcome bottlenecks in non-viral gene delivery. This funding will accelerate the development of fit-for-purpose delivery vehicles through a delivery-as-a-service model.